X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Idelalisib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CAL101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $81.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 22, 2024
Details:
Zydelig® (idelalisib) is approved in the U.S. for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.
Lead Product(s): Idelalisib
Therapeutic Area: Oncology Product Name: Zydelig
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
